A shareholder firm called for the Food and Drug Administration to halt Cassava Sciences' (SAVA) studies in Alzheimer's disease, leading SAVA stock to plummet Wednesday.
Cassava is working on an Alzheimer's treatment called simufilam which binds to and stabilizes an altered version of the protein filamin A. But a "whistleblower submission" from Labaton Sucharow calls into question three major areas of concern and six smaller concerns surrounding the company's data. The firm claims Cassava engaged in "data manipulation and misrepresentation."
The company responded to the Labaton Sucharow's claims saying it "stands behind its science, its scientists and its scientific collaborators."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.